US2011117119A1PendingUtilityA1

Novel compositions and methods

58
Assignee: METTENS PASCALPriority: Jul 25, 2008Filed: Jul 24, 2009Published: May 19, 2011
Est. expiryJul 25, 2028(~2 yrs left)· nominal 20-yr term from priority
Inventors:Pascal MettensJames Raymond BrownDennis Murphy
A61P 37/04A61P 31/06A61K 49/00C07K 14/35A61K 39/04
58
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention is directed to a polypeptide which comprises: (i) an Rv3616c protein sequence; (ii) a variant of an Rv3616c protein sequence; or (iii) an immunogenic fragment of an Rv3616c protein sequence for use in the treatment or prevention of latent TB. In other aspects the invention is directed to associated polynucleotides, fusion proteins and methods for the treatment or prevention of latent tuberculosis.

Claims

exact text as granted — not AI-modified
1 - 45 . (canceled) 
     
     
         46 . A method for the treatment or prevention of latent tuberculosis comprising the administration of a polypeptide comprising:
 (i) an Rv3616c protein sequence;   (ii) a variant of an Rv3616c protein sequence; or   (iii) an immunogenic fragment of an Rv3616c protein sequence;   
       to a subject in need thereof, wherein said polypeptide induces an immune response. 
     
     
         47 . A method for the treatment or prevention of latent tuberculosis comprising the administration of a polynucleotide comprising a nucleic acid sequence encoding a polypeptide comprising:
 (i) an Rv3616c protein sequence;   (ii) a variant of an Rv3616c protein sequence; or   (iii) an immunogenic fragment of an Rv3616c protein sequence;   
       to a subject in need thereof, wherein said polynucleotide induces an immune response. 
     
     
         48 - 51 . (canceled) 
     
     
         52 . The method according to  claim 46 , wherein the subject has active tuberculosis. 
     
     
         53 . The method according to  claim 46 , wherein the subject has latent tuberculosis. 
     
     
         54 . The method according to  claim 46 , wherein the subject does not have tuberculosis. 
     
     
         55 - 66 . (canceled) 
     
     
         67 . The method according to  claim 46 , wherein the treatment or prevention of latent tuberculosis refers to the treatment of latent tuberculosis. 
     
     
         68 . The method according to  claim 46 , wherein the treatment or prevention of latent tuberculosis refers to the prevention of latent tuberculosis. 
     
     
         69 . The method according to  claim 46 , wherein the treatment or prevention of latent tuberculosis refers to the prevention of reactivation of tuberculosis. 
     
     
         70 . The method according to  claim 46 , wherein the treatment or prevention of latent tuberculosis refers to the delay of reactivation of tuberculosis. 
     
     
         71 - 86 . (canceled) 
     
     
         87 . The method according to  claim 47 , wherein the subject has active tuberculosis. 
     
     
         88 . The method according to  claim 47 , wherein the subject has latent tuberculosis. 
     
     
         89 . The method according to  claim 47 , wherein the subject does not have tuberculosis. 
     
     
         90 . The method according to  claim 47 , wherein the treatment or prevention of latent tuberculosis refers to the treatment of latent tuberculosis. 
     
     
         91 . The method according to  claim 47 , wherein the treatment or prevention of latent tuberculosis refers to the prevention of latent tuberculosis. 
     
     
         92 . The method according to  claim 47 , wherein the treatment or prevention of latent tuberculosis refers to the prevention of reactivation of tuberculosis. 
     
     
         93 . The method according to  claim 47 , wherein the treatment or prevention of latent tuberculosis refers to the delay of reactivation of tuberculosis. 
     
     
         94 . The method according to  claim 46 , wherein the polypeptide comprises an amino acid sequence at least 90% identical to SEQ ID NO:1. 
     
     
         95 . The method according to  claim 47 , wherein the polynucleotide comprises a nucleic acid sequence at least 90% identical to SEQ ID NO:2.

Join the waitlist — get patent alerts

Track US2011117119A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.